Search

everythinglearnresearchcommunity

for

Search:↓

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The conversation discusses Procapil, a treatment for hair loss containing Apigenin and Oleanolic acid. Users are sharing their experiences and asking if anyone has tried it.

The user experienced hair regrowth using Koshine KX-826 after two months, noticing new baby hairs and reduced shedding, while continuing to use Hims spray. They reported no side effects from Koshine and plan to keep monitoring progress.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.

Combining topical minoxidil and pyrilutamide (KX-826) for hair loss treatment. It is suggested to apply minoxidil first, wait 20 minutes, then apply pyrilutamide for better absorption.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

KX-826 may cause increased hair loss for some users, leading to concerns about its effects. One user reported no issues but also no hair regrowth, only maintenance.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

The post and conversation discuss different methods of applying hair loss treatments directly to the scalp. The original poster suggests using a 1ml TB Syringe & Ophthalmic Cannula for precise application, while others share their own methods, including sprays, droppers, and simple syringes.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The user experienced eyebrow hair loss and tried various treatments, including Minoxidil, a Capsaicin-based product, Latanoprost, Bimatoprost, Castor Oil, and Travoprost. Despite initial setbacks and a brutal shedding phase, they eventually saw positive results with Travoprost, encouraging others not to give up on treatments.

The user is experiencing hair regrowth using finasteride, minoxidil, and KX-826. They regret not starting treatment earlier but are now seeing progress.

The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The conversation discusses the application frequency of Koshine 1% for hair loss, with conflicting instructions between Amazon and the main website. The user is unsure whether to apply it once or twice daily.

The conversation discusses the use of KX826 for hair loss, with mixed opinions on its effectiveness. Some users are skeptical, mentioning no significant progress or regrowth, and others suggest it might be a scam or that data may be manipulated.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.